KBP Biosciences Presentation at the 18th Global CardioVascular Clinical Trialist Forum To Present the New Treatment Options for Resistant Hypertension in CKD patients
Dec 10, 2021
  • The 18th Global CardioVascular Clinical Trialist Forum was held December 2-5, 2021. The conference gathered top industry experts and KOLs from around the world to share their opinions on recent developments within the cardiovascular clinical development therapeutic landscape.

  • KBP Biosciences had been invited to attend the CVCT for many years and was honored to co-host the very first CVCT China session this year. Fred Yang, Ph.D., Chief Development Officer of KBP, the co-chair of the CVCT China session, presented “Resistant Hypertension in CKD Patients - Patient Care and Treatment Options in China” which outlines the epidemiology and current standard of care of hypertension in advanced CKD patients in China.


PRINCETON, N.J., 10 December 2021 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced that it co-sponsored the 18th Global CardioVascular Clinical Trialist Forum was held December 2-5, 2021. KBP Biosciences had been invited to attend the CVCT for many years and was honored to co-host the very first CVCT China session this year. The conference gathered top industry experts and KOLs from around the world to share their opinions on recent developments within the cardiovascular clinical development therapeutic landscape.

“This is the first time CVCT included a China-specific multi-stakeholders’ session, the presentations by the faculty provided a comprehensive overview of the cardiorenal metabolic disease area and is an important first step for Chinese physicians and clinical researchers to participate in a truly global dialogue,” said Faiez Zannad MD, Director and organizer of the CVCT Forum.

According to Medicare, approximately $1 out of every $5 spent by Medicare is used for CKD patients. Now the cost for patients with CKD is approaching $120 billion per year. Current estimates of the prevalence of CKD indicate that there are 138 million adults with CKD in China alone. Available MRAs can provide additional blood pressure control in some of these patients, but usually will increase the risk of hyperkalemia. Many patients with stage 3b/4 CKD are at their maximum tolerated dose of anti-hypertensive medications and still have uncontrolled or resistant hypertension. Therefore, current available MRAs are either contraindicated or must be used with extreme caution. 

Fred Yang, Ph.D., Chief Development officer of KBP, co-chaired the first-ever China focused CVCT session. Dr. Yang presented “Resistant Hypertension in CKD patients - Patient Care and Treatment Options in China” which outlines the epidemiology and current standard of care of hypertension in advanced CKD patients in China. Dr. Yang also stated “In China alone, uncontrolled or resistant hypertension occurs in approximately 60% of patients with advanced CKD. KBP-5074 is a non-steroidal MRA discovered and developed by KBP Biosciences.  The initial indication is uncontrolled HTN in advanced CKD patients. The Phase 3 study of KBP-5074 has been started around the world.”

1

(Photo: KBP Biosciences Lab)

2

(Photo: KBP Biosciences Lab)

Jiguang Wang, MD, Shanghai Ruijin Hospital, President of the Chinese Hypertension League, Director of The Shanghai Institute of Hypertension, said “Uncontrolled especially Resistant hypertensionin patients with chronic kidney disease is a major cardiovascular challenge in China and around the world. Based on the data from Phase 2b study (BLOCK-CKD),  KBP-5074 could  be the potential solution for the global unmet medical needs.”

“Increasing awareness of resistant hypertension in patients with CKD in China reinforces the need to address this condition from a global perspective,” said Bertram Pitt, MD, University of Michigan and co-chair of CVCT.

 “KBP continues to support the cardiorenal community by developing new medicines for this important disease area,”  stated Zhenhua Huang, Chairman and Founder of KBP Biosciences.


About The Global CardioVascular Clinical Trialists Workshop (CVCT)

The Global CardioVascular Clinical Trialists Workshop is a high-level, private meeting with an exceptional expert faculty, endorsed/supported by Inserm, NHLBI, ESC Working Group on CV Pharmacology and Drug Therapy, FDA, EMEA and Duke Heart Center. CVCT Workshops have become the authoritative meeting place for cardiovascular trial principal investigators, statisticians, Pharma R&D experts and regulators from the major transatlantic agencies. Brainstorming topics include CV drugs, device and biomarker development and trial design, conduct, ethics, interpretation, approvability and implementation. CVCT Workshop involves a limited number of participants and includes distinguished cardiologists, clinical trialists, principal investigators and statisticians from academia as well as senior R&D pharma doctors and NIH, EMEA-CPMP and FDA doctors.


About KBP Biosciences

KBP Biosciences is a global, clinical-stage biotech company focused on research and development of new chemical entities with known mechanisms of action targeting underserved patient populations. Headquartered in Princeton, NJ, KBP Biosciences has strong capabilities from discovery and CMC through global clinical development and registration. The company principally devotes its resources in three therapeutic areas: major organ protection, anti-infectives and respiratory inflammation.

KBP has built a proprietary R&D platform aimed at the discovery and development of global first-in-class compounds. The platform includes a compound library as basis of new compound discovery, a library of multi-drug resistant bacteria, and an in vivo pharmacology platform for screening and testing new compounds. KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.


About KBP-5074

KBP-5074 is a non-steroidal MRA discovered and developed by KBP Biosciences.  KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. KBP-5074 has been investigated in 9 clinical studies including the BLOCK-CKD Phase 2b study. The Phase 3 study has been started in close consultation with the division of Cardiology and Nephrology of FDA.


About Advanced CKD and Uncontrolled Hypertension

In the US alone, uncontrolled hypertension and stage 3b and 4 CKD afflict more than 3 million patients in whom currently available MRAs are either contraindicated or must be used with extreme caution due to the risk of hyperkalemia. Treatments that lower blood pressure are available and include ACE-Is, ARBs, and diuretics among others.  Many patients with stage 3b/4 CKD are at their maximum tolerated dose and still have uncontrolled or resistant hypertension.  Available MRAs can provide additional blood pressure control in some of these patients, but usually will increased risk of hyperkalemia.

For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/.


Contacts:

Investor Relations:

ir@kbpbiosciences.com


Public Relations:

pr@kbpbiosciences.com